Field
This application relates generally to the field of intraocular devices. More particularly, this application is directed to intraocular implants and lenses (IOLs) with an aperture to increase depth of focus (e.g. “masked” intraocular lenses), and methods of making the same.
Description of the Related Art
The human eye functions to provide vision by transmitting and focusing light onto the retina using the cornea and the natural crystalline lens. The quality of the focused image depends on many factors including the size and shape of the eye, and the optical power of the cornea and the lens.
Some people suffer from cataracts in which the crystalline lens undergoes a loss of transparency. In such cases, the natural crystalline lens can be removed and replaced with an artificial intraocular lens (IOL).
A method is disclosed herein, the method comprising: providing an intraocular lens, the intraocular lens comprising a lens body and a mask with an aperture for improving depth of focus; and creating a plurality of fractures in the mask. The plurality of fractures in the mask can be created by manipulating the intraocular lens, such as while injecting the intraocular lens into an eye.
An intraocular lens is also disclosed herein, the intraocular lens comprising: a lens body; and a mask with an aperture for improving depth of focus, wherein the mask is configured to fracture along a plurality of fracture pathways when the intraocular lens is manipulated.
The mask can include a plurality of fracture management locations that cause the plurality of fractures to be more likely to form along selected fracture pathways. The plurality of fracture management locations can be configured to substantially maintain the position of the mask with respect to the lens body after creating the plurality of fractures as compared to the position of the mask with respect to the lens body before creating a plurality of fractures.
The lens body can comprise lens material, wherein the lens material extends through the plurality of holes. The mask can be embedded in the lens body.
The lens body can comprise a lens material that is elastic and the mask can comprise a mask material that is brittle. The mask material can be one that fractures at an elongation of approximately 5% or less. The lens material can be one that fractures at an elongation of approximately 150% or more. In some embodiments, the mask material comprises a blend of approximately 30% polymethyl methacrylate (PMMA) and 70% polyvinylidene difluoride (PVDF).
Various embodiments are depicted in the accompanying drawings for illustrative purposes, and should in no way be interpreted as limiting the scope of the embodiments. Furthermore, various features of different disclosed embodiments can be combined to form additional embodiments, which are part of this disclosure.
Some vision problems, such as cataracts, can be treated by implantation of an artificial intraocular lens (IOL). However, depending upon the type of IOL that is used, the patient may still suffer from defects in his or her non-distance eyesight (e.g., due to the inability to vary accommodation so as to focus on near objects). One technique for treating such defects is by including a mask within the IOL that increases the patient's depth of focus. The intraocular implants of the embodiments described herein include a mask adapted to provide a small aperture for light to pass through to the retina to increase depth of focus using the pinhole effect. The light rays that pass through the mask aperture within the IOL converge at substantially a single focal point on the retina, while the light rays that would not converge at the single point on the retina are blocked by the mask.
One method of implanting the IOL 1000 can include inserting the IOL through a small incision in the eye. The IOL 1000 can be inserted into the eye using an injector system. The injector system can include a cartridge tip for housing the IOL 1000. The size of the hole in the cartridge tip through which the IOL 1000 is injected is typically smaller than the size of the IOL. Thus, the IOL 1000 is deformed (e.g., stretched) when passing through the tip during the injection process. The IOL 1000 can be made of a resilient material such that it can revert back to its pre-injection shape after passing through the cartridge tip. When using this method of implantation, the size of the incision is generally dependent on the size of the cartridge tip. Typically, smaller surgical incisions are associated with better surgical outcomes. However, injecting the IOL 1000 through a smaller hole places more strain on the IOL as it is deformed to pass through the injector.
The size of the cartridge tip and incision can be limited by the material properties of the lens body. This problem can be further complicated by the embedded mask 1008 within the IOL 1000. For example, as the IOL 1000 is pushed through the cartridge tip, the extrusion forces can not only stretch or otherwise deform the IOL but also the embedded mask 1008. In addition, the location of the embedded mask 1008 within the IOL 1000 can be displaced (e.g., the embedded mask can become transversely de-centered and/or longitudinally biased to either side of the desired longitudinal depth of the embedded mask within the IOL).
The mask 1008 and the lens body 1002 may typically be manufactured from dissimilar materials. For example, the mask material and the lens body material may have differences in mechanical properties such as tensile strength (yield strength and/or ultimate strength) and/or elongation under a load. These differences in mechanical properties between the lens body material and the mask material create challenges for the combined IOL 1000 in relation to survival of lens folding and extrusion events that occur during the normal process of lens insertion. After releasing the IOL 1000 from the cartridge tip, it is desirable that the IOL 1000 and the embedded mask 1008 achieve a target post-injection optical performance specification (e.g., optical power, presbyopia correction, etc.). For example, it may be desirable for the post-injection optical performance to substantially match the pre-injection optical performance. However, owing to the differing mechanical properties of the mask material and the lens body material, an IOL constructed with an embedded mask 1008 may be prone to demonstrating relatively poorer optical restoration performance in the post-injection condition.
One solution to the problem of needing to inject the IOL 1000 through a relatively small hole without reducing the optical performance of the IOL, is to provide that both the lens body 1002 and the embedded mask 1008 have similar material properties (e.g., elasticity) that allow them to both spring back to their pre-injection shapes, and, in the case of the embedded mask, its pre-injection location within the IOL. This solution is discussed in U.S. patent application Ser. No. 14/454,585, entitled “INTRAOCULAR LENS WITH ELASTIC MASK,” the entirety of which is incorporated by reference herein in its entirety. The following disclosure describes another approach to solving this problem which may be more readily applied to an IOL 1000 where the lens body 1002 and the mask 1008 are made of relatively dissimilar materials.
Embodiments described herein mitigate the difficulties associated with maintaining pre-injection and post-injection optical performance consistency for an IOL 1000 which has a lens body 1002 and an embedded mask 1008 constructed from dissimilar materials. According to some embodiments, the mask 1008 is designed to fracture in a managed way during the lens folding and/or lens injection events. The mask 1008 can be designed with, for example, brittleness and low fracturing forces, while the lens body 1002 can be designed with greater elasticity and relatively longer elongation properties. After the mask 1008 has fractured, the resiliency of the lens body 1002 can relatively freely restore the mask 1008 to its pre-injection shape and/or location upon relaxation. Thus, upon relaxation of the lens body 1002 after injection, the optical performance characteristics of the lens body 1002 in combination with the mask 1008 can be restored.
Provided below are examples of IOLs with embedded masks that are designed to overcome the issues described above. In some implementations, the IOLs (e.g., 1000) with embedded masks (e.g., 1008) that are described herein include substantially the same optical characteristics pre-injection and post-injection.
Masks
The mask 2034b can have dimensions adapted to function with the implant body to improve a patient's vision. The mask 2034b can be symmetrical, e.g., symmetrical about a mask axis 2039b. In some embodiments, the outer periphery of the mask 2034b can be circular. The mask 2034b in general can have an outer diameter of at least about 3 mm and/or less than about 6 mm. In some embodiments, the mask 2034b can be circular and can include a diameter of at least about 3 mm and/or less than or equal to about 4 mm. In some embodiments, the mask 2034b can be circular and can include a diameter of about 3.2 mm.
In some embodiments, the aperture 2038b can be substantially circular and can be substantially centered in the mask 2034b. The size of the aperture 2038b can be any size that is effective to increase the depth of focus of an eye of a patient with presbyopia. In particular, the size of the aperture 2038b can be dependent on the location of the mask within the eye (e.g., distance from the retina). In some embodiments, the aperture 2038b can have a diameter of at least about 0.85 mm and/or less than or equal to about 2.2 mm. In certain embodiments, the diameter of the aperture 2038b is less than or equal to about 2 mm. In some embodiments, the diameter of the aperture 2038b is at least about 1.1 mm and/or less than or equal to about 1.6 mm. In some embodiments, the diameter of the aperture 2038b is at least about 1.3 mm and/or less than or equal to about 1.4 mm.
The aperture 2038b can transmit substantially all incident light along the mask axis 2039b. The annular region 2036b can substantially prevent transmission of incident light thereon. The aperture 2038b can be a through-hole in the annular region 2036b or a substantially light transmissive (e.g., transparent) portion thereof. The aperture 2038b of the mask 2034b can be generally defined within the outer periphery of the mask 2034b.
The annular region 2036b can at least partially prevent transmission of visible light through the mask 2034b. For example, in some embodiments, the annular region 2036b can prevent transmission of substantially all or at least a portion of the spectrum of the incident visible light. In some embodiments, the annular region 2036b can prevent transmission of substantially all visible light, e.g., radiant energy in the electromagnetic spectrum that is visible to the human eye. The annular region 2036b can substantially prevent transmission of radiant energy outside the range visible to humans in some embodiments.
Preventing transmission of light through the annular region 2036b can decrease the amount of light that reaches the retina and the fovea that would not converge at the retina and fovea to form a sharp image. As discussed above, the size of the aperture 2038b is such that the light transmitted therethrough generally converges at the retina or fovea. Accordingly, a much sharper image can be presented to the retina than would otherwise be the case without the mask 2034b.
In some embodiments, the annular region 2036b can prevent transmission of at least about 90 percent of incident light. In some embodiments, the annular region 2036b can prevent transmission of at least about 92 percent, at least about 95 percent, or at least about 98 percent of all incident light. The annular region 2036b of the mask 2034b can be substantially opaque to prevent the transmission of light.
In some embodiments, the annular region 2036b can transmit no more than about 5% of incident visible light. In some embodiments, the annular region 2036b can transmit no more than about 3 percent of incident visible light. In some embodiments, the annular region 2036b can transmit no more than about 2 percent of incident visible light. In some embodiments, at least a portion of the annular region 2036b can be opaque to more than 99 percent of the light incident thereon.
As discussed above, the annular region 2036b can prevent at least partial transmission of light without absorbing the incident light. For example, the mask 2034b can be reflective or can interact with the light in a more complex manner, as discussed in U.S. Pat. No. 6,554,424, issued Apr. 29, 2003, which is hereby incorporated by reference in its entirety.
The annular region 2036b can be at least partially opaque or can be completely opaque. The degree of opacity of the annular region 2036b can prevent at least some or substantially all light from being transmitted through the mask 2034b. Opacity of the annular region 2036b can be achieved in any of several different ways. For example, the material used to make mask 2034b can be naturally opaque. As another example, the material used to make the mask 2034b can be substantially clear, but treated with a dye or other pigmentation agent to render region 2036b substantially or completely opaque. In certain embodiments, the mask can include carbon black. In yet another example, the surface of the mask 2034b can be treated physically or chemically (such as by etching) to alter the refractive and transmissive properties of the mask 2034b and make it less transmissive to light.
In some embodiments, a photochromic material can be used as the mask or in addition to mask. Under bright light conditions, the photochromic material can darken thereby creating a mask and enhancing near vision. Under dim light conditions, the photochromic material can lighten, which allows more light to pass through to the retina. In certain embodiments, under dim light conditions, the photochromic material lightens to expose an optic of the intraocular implant. Further photochromic material details are disclosed in U.S. Patent Publication No. 2013/0268071, filed Nov. 30, 2012, which is hereby incorporated by reference in its entirety.
The mask can transition between different degrees of opacity. For example, at least a portion of the mask can transition between at least a first degree of opacity and a second degree of opacity. Further details are disclosed in U.S. application Ser. No. 13/802,340, filed Mar. 13, 2013, which is hereby incorporated by reference in its entirety.
In some embodiments, the opacity of the mask can also vary in different regions of the mask. For example, the opacity of the outer edge and/or the inner edge of the mask can be less than the central region of the mask. The opacity in different regions can transition abruptly or have a gradient transition. Additional examples of opacity transitions can be found in U.S. Pat. Nos. 5,662,706, 5,905,561, 5,965,330, and 8,858,624, all of which are hereby incorporated by reference in their entirety.
In some embodiments, the fracturable mask 1008 includes a plurality of fracture management locations 1012. The fracture management locations 1012 cause the mask 1008 to be more likely to fracture along selected fracture pathways. For example, fractures may form along pathways connecting adjacent fracture management locations 1012. Fracture pathways can be selected, for example, by providing fracture management locations 1012 along the desired paths that the fractures are to follow. As discussed further herein, in some embodiments, the fracture management locations are holes that extend through the thickness of the mask 1008 between its anterior and posterior surfaces. In such embodiments, fractures may be more likely to form between each hole and its neighboring hole(s). A series of holes along a desired pathway, or multiple pathways, can create weaknesses that make a fracture, or fractures, more likely to occur along the pathway(s) of holes, similar to how perforations in a sheet of paper help to guide a tear in the sheet of paper. However, in other embodiments, the fracture management locations 1012 can be embodied in other ways, including as weak points and/or impurities in the mask material. Again, the weak points and/or impurities can be arranged so as to make the mask more likely to fracture along a desired pathway or pathways. For example, fractures may be more likely to form between each weak point/impurity and the neighboring weak point(s)/impurity (or impurities). In some embodiments, the fracture management locations 1012 are arranged randomly throughout the fracturable mask 1008 (as shown in
The fracturable mask 1008 can be designed to fracture relatively easily. This can be done, for example, by forming the fracturable mask 1008 out of a material that is brittle as compared to the lens body material. In some embodiments, the mask material is selected to exhibit elongation at fracture of about 5% or less, or about 3% or less, or about 2% or less. In contrast, the lens material can be selected to exhibit elongation at fracture of about 150% or more. The fracturable mask 1008 can also be made to fracture relatively easily by making the mask relatively thin. In some embodiments, the fracturable mask 1008 is less than approximately 10μ thick, or less than about 6μ thick. In contrast, the lens body 1002 can be at least about 500 times greater in cross-sectional thickness than the mask 1008.
Since the mask 1008 fractures relatively easily, a plurality of fractures can be intentionally formed in the mask while manipulating the resilient lens body 1002. Once the mask has fractured at a plurality of locations, the elastic resiliency of the lens body 1002 can restore the mask 1008 to substantially its same shape and/or location prior to having manipulated the lens body 1002. The fractures are so small, however, that they do not substantially affect the optical performance of the mask 1008.
Materials from which to construct the fracturable mask 1008 can be selected based upon, for example, tensile strength (yield strength and/or ultimate strength) and/or elongation characteristics. Such characteristics can be determined by measuring the stress-strain relationship of a sample made from a selected material.
As shown in
As illustrated in
As discussed herein, in some embodiments, the fracturable mask 1008 includes a plurality of holes which serve as fracture management locations. In some embodiments, there are at least about 3000 such holes randomly distributed throughout the fracturable mask 1008. Such holes not only serve to cause the mask to fracture in a managed way but they also serve the additional function of mechanically locking the fracturable mask 1008 in place with respect to the lens body 1002. This is true because lens body material can be made to extend through the holes to create a plurality of material bridges that extend between the anterior and posterior surfaces of the fracturable mask 1008. These material bridges remain post-fracture and substantially maintain the pre-fracture position of the fracturable mask 1008 with respect to the lens body 1002 even after fracturing has occurred. Embodiments of fracturable masks with holes serving as the fracture management locations are illustrated in
The mask 2100 can include a plurality of holes 2120. When the mask 2100 is embedded in the lens body, the lens body can extend at least partially through the holes, thereby creating a bond (e.g. material “bridge”) between the lens body on either side of the mask. Further disclosure regarding the material “bridge” can be found in U.S. Publication No. 2011/0040376, filed Aug. 13, 2010, which is incorporated by reference herein in its entirety.
The holes 2120 of the mask 2100 shown in
The holes in the mask serve at least two purposes: the holes provide some light transmission and, as just discussed with respect to
It can be desirable to decrease or minimize the total amount of light that passes through the mask in order to increase or maximize near image contrast. Delamination can be prevented with a relatively small total area of the mask having holes for “bridges”. For example, an area of about 3% of the mask can include holes which can balance increasing or maximizing mechanical strength and reducing or minimizing optical effects of the holes. In certain embodiments, the anterior surface of the mask has a mask surface area, and the light transmission structures (e.g., holes) in the mask have a total area on the anterior surface of the mask of about 1% to about 5% of the mask surface area. To limit the visual impact of diffraction of light passing through the holes of the mask, the holes can be made as small as possible. The Airy disc from each hole is larger the smaller the hole size, so the composite diffraction pattern produced by the pattern of holes becomes larger as well. The composite diffraction pattern spreads light over a larger portion of the retina, decreasing the local brightness of diffracted light and making diffraction artifacts less visible to the patient. Diffraction patterns produced by a pattern of holes also tends to have a chromatic component such that the diffraction halo tends to graduate in color radially. Varying the size of the holes produces this effect in multiple scales, which scrambles the color of the halo. This reduces color contrast in the halo, making it less noticeable.
The outer diameter of the outer periphery of the mask can be varied. In certain embodiments, the outer diameter is selected to selectively allow an amount of light to pass to the retina of the eye. The pupil of the eye changes size in different lighting conditions. In low light situations, the pupil of the eye enlarges to let more light into the eye. The outer diameter can be selected so that light does not pass outside the outer periphery of the mask in relatively high light conditions, and so that at least some light can pass outside the outer periphery of the mask in relatively low light conditions. The pupil size of patients often can vary; therefore, the outer diameter of the mask can be selected for a specific patient pupil size. For example, for patients with relatively small pupils, dim light may present more of a vision issue than for patients with larger pupils. For smaller-pupil patients, a mask with more light transmission and/or a smaller outer diameter will increase light reaching the retina and improve vision in dim light situations. Conversely, for larger pupil patients, less light transmission and/or a larger outer diameter mask may improve low-contrast near vision and block more unfocused light. The masked IOLs of the present application give the surgeon flexibility to prescribe the appropriate combination of masked IOL features for particular patients.
In certain embodiments, the center of the aperture of the mask is off-center to the center of the lens body. By having an aperture off-center to the optical center of the lens body, the intraocular lens can be rotated during the implantation procedure so that the optical center of the patient's eye can be aligned with the center of the aperture. The vision of the patient can be improved by aligning the optical center of the patient's eye with the aperture center.
In some embodiments, the mask 2100 can include an annular region near the outer periphery 2124 of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the outer periphery 2124 of the mask 2100.
In some embodiments, the mask can include an annular region around the inner periphery of the mask having no holes. In certain embodiments, there are no holes within 0.1 mm of the aperture 2128.
In some embodiments, the holes 2120 each have the same diameter. In certain embodiments, the holes 2120 can include one or more different diameters. In some embodiments, the diameter of any single hole 2120 is at least about 0.01 mm and/or less than or equal to about 0.02 mm. In some embodiments, the diameter of the holes 2120 can vary within 0.001 mm of one or more of the following hole diameters: 0.010 mm, 0.013 mm, 0.016 mm, and/or 0.019 mm. In some embodiments, holes of different diameters are interspersed throughout at least a portion of the mask 2100. In some embodiments, the holes are interspersed at irregular locations throughout at least a portion of the mask 2100.
In certain embodiments, the mask includes holes greater than about 7 microns in diameter (e.g., greater than a cross-sectional area of about 35 μm2), and preferably greater than about 10 microns in diameter (e.g., greater than a cross-sectional area of about 75 μm2). In certain embodiments, the mask includes holes greater than about 7 microns in diameter (e.g., greater than a cross-sectional area of about 35 μm2) and less than about 20 microns in diameter (e.g., less than a cross-sectional area of about 320 μm2). In further embodiments, the mask includes holes less than about 50 microns in diameter (e.g., less than a cross-sectional area of about 2000 μm2. Holes with diameters less than 7 microns may not be large enough for lens material such as silicone or acrylic to enter and migrate to form a bridge. However, the viscosity of the lens material will determine whether the material will be able to migrate into the hole to form the bridge and a minimum cross-sectional area of the hole may be dependent on the material of the implant body. If the material of the implant body does not migrate into a hole, that hole may create a bubble that could interfere with the visual performance of the implant.
In a certain embodiment, the mask includes randomly or pseudo-randomly placed holes across the mask. The mask can include holes with one of four hole diameters within the parameters provided above. There can be an equal number of holes with each hole diameter. An algorithm can be used to randomly or pseudo-randomly assign the variously sized holes to locations across the mask annulus. The rules for the randomization program can include (1) that there be no “collisions” of the holes (e.g., the holes have no contact with each other), (2) that no holes interfere with the inner and outer peripheral edges of the mask, and (3) that the holes are placed in such a way as to create substantial uniform density across the mask annulus. For example, the rules for the randomization program may include one or more of these rules.
In some embodiments, there are at least about 1000 holes and/or less than or equal to about 2000 holes. In some embodiments, there are at least about 1000 holes and/or less than or equal to about 1100 holes. In some embodiments, the number of holes is within ten holes of about 1040 holes. In some embodiments, there are an equal number of holes of each diameter. In some embodiments, the number of holes having each diameter is different.
In some embodiments, the holes are interspersed at irregular locations throughout at least a portion of the mask 2100. In some embodiments, holes of different diameters are evenly interspersed throughout at least a portion of the mask 2100. For example, the mask 2100 can include a plurality of non-overlapping hole regions. The sum of the surface area of the plurality of non-overlapping hole regions can equal the total surface area of the entire hole region of the mask. In some implementations, each region of the plurality of regions can include a number of holes, each of the holes having a different diameter. In some implementations, the number of holes in each region can equal the number of different hole sizes in the entire hole region. In some implementations, an amount of open area within each hole region can be substantially the same. In some implementations, each hole region can include the same number of holes.
Methods of Use
Any of the IOLs described herein can be implanted using an injection system. The method can include intentionally fracturing the mask embedded in the IOL by, for example, injecting the IOL through a small cartridge tip. The cartridge tip may have an inside diameter of less than or equal to about 2.0 mm, for example, within about 0.2 mm of about 1.5 mm, preferably less than or equal to about 1.5 mm, such as between about 1.5 mm and about 1.25 mm or between about 1.25 mm and about 1.0 mm. The injection system can deliver the IOL through an incision having a chord length of less than or equal to about 2.4 mm. The IOL can be configured to transition between a pre-injection configuration (e.g., rolled up for implantation) and a post-injection configuration (expanded, in-situ shape). The pre-injection configuration can be substantially smaller than the post-injection configuration.
In some implementations, it can be desirable for the IOL to transition between the pre-injection configuration and the post-configuration without substantially changing optical performance. For example, the optical power of the IOL prior to injection can be within about 0.5 diopters, preferably within about 0.3 diopters, or within about 0.2 diopters, or within about 0.1 diopters, of the optical power of the IOL after injection.
Methods of Manufacturing
Various techniques can be used for forming the mask. In some embodiments, the mask can be formed using a mask material alone or in combination with an opacification agent. The mask material can include any of the mask materials described herein, for example, PVDF, silicone, or an acrylic copolymer (e.g., PMMA). In some implementations, the mask material can be combined with an opacification agent, such as carbon black, or any class 3 medical device material.
In some embodiments, the resulting mixture can be used to form a mask film having a thickness equal to the desired mask thickness. Techniques for forming the mask film can include allowing mask material to spread to a desired thickness by gravity or by spinning. Each mask can then be formed from the mask film using a stamp, sieve, die, laser, or other machine. In an alternative technique, the mask material can be formed into a tube (e.g., using an extrusion process), and masks having the desired thickness can be cut from the tube. Further mask materials and methods of making a mask are disclosed in U.S. Pub. No. 2011/0040376, filed Aug. 13, 2010, which is incorporated by reference herein in its entirety.
After forming the mask, the mask can be embedded within or applied to a lens body. For example, the method can include pre-dosing a first lens forming mold portion with a first amount of lens material and positioning the mask on a positioning mold portion. Thereafter, the first lens forming mold portion and the positioning mold portion can be joined together, and the lens material can be at least partially cured. After partially curing the lens material, at least the first lens forming mold portion can be cooled to facilitate the separation of the mold portions without disrupting the position of the mask. Once the mold portions are separated, a second amount of lens material can be added to the first lens forming mold portion and/or a second lens forming mold portion, and the first lens forming mold portion and the second lens forming mold portion can be joined together. In this configuration, the first and the second amounts of lens material can be at least partially cured, for example, using a light cure. Finally, the final curing process can be carried out using thermal curing. In some implementations, depending on the mask and lens materials, the IOL can undergo chemical extraction to remove any impurities. Further details regarding this manufacturing method or alternatives can be found in U.S. patent application Ser. No. 13/830,889 and U.S. Publication No. 2014/0131905, both filed Mar. 14, 2013, which are incorporated by reference herein in their entireties.
Alternatively, the intraocular lens can be manufactured using stereolithography to image the mask within the lens. The method can include providing a first amount of photoreactive lens material. Next, the method can also include forming a first layer of the intraocular lens by curing the first amount of photoreactive lens material to form the desired shape. Thereafter, the method can include providing a second amount of photoreactive lens material over the cured first layer and forming a second layer of the intraocular lens by curing the second amount of photoreactive lens material to form the desired shape. This process can be repeated to additively form the lens. After one or more initial layers of the lens have been formed, a mask can be imaged within the initial layers by activating dyes such as those described in U.S. Publication No. 2013/0268071, filed Nov. 30, 2012, and U.S. Pat. No. 8,604,098, filed Jul. 6, 2011, which are incorporated by reference herein in their entireties, by laser ablation, or by other methods to create opacity, as described in U.S. Publication 2013/0289543, filed Mar. 12, 2013, which is also by incorporated by reference herein in its entirety. Once the mask is in place, the process of providing and curing layers of photoreactive lens material can be continued such that the mask is embedded within the completed lens. The lens can be formed such that the mask can be imaged within the lens in a manner that provides the mask with the same physical properties as the lens, thus allowing the mask to flex with the lens without damage.
Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, and/or steps. Thus, such conditional language is not generally intended to imply that features, elements, and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, and/or steps are included or are to be performed in any particular embodiment.
The terms “approximately,” “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
Although certain embodiments and examples have been described herein, it will be understood by those skilled in the art that many aspects of the methods and IOLs shown and described in the present disclosure may be differently combined and/or modified to form still further embodiments or acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. A wide variety of designs and approaches are possible. No feature, structure, or step disclosed herein is essential or indispensable.
Some embodiments have been described in connection with the accompanying drawings. However, it should be understood that the figures are not drawn to scale. Distances, angles, etc. are merely illustrative and do not necessarily bear an exact relationship to actual dimensions and layout of the devices illustrated. Components can be added, removed, and/or rearranged. Further, the disclosure herein of any particular feature, aspect, method, property, characteristic, quality, attribute, element, or the like in connection with various embodiments can be used in all other embodiments set forth herein. Additionally, it will be recognized that any methods described herein may be practiced using any device suitable for performing the recited steps.
For purposes of this disclosure, certain aspects, advantages, and novel features are described herein. It is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment. Thus, for example, those skilled in the art will recognize that the disclosure may be embodied or carried out in a manner that achieves one advantage or a group of advantages as taught herein without necessarily achieving other advantages as may be taught or suggested herein.
Moreover, while illustrative embodiments have been described herein, the scope of any and all embodiments having equivalent elements, modifications, omissions, combinations (e.g., of aspects across various embodiments), adaptations and/or alterations as would be appreciated by those in the art based on the present disclosure. The limitations in the claims are to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive. Further, the actions of the disclosed processes and methods may be modified in any manner, including by reordering actions and/or inserting additional actions and/or deleting actions. It is intended, therefore, that the specification and examples be considered as illustrative only, with a true scope and spirit being indicated by the claims and their full scope of equivalents.
This application claims priority benefit under 37 C.F.R. § 119(e) to U.S. Provisional Patent Application No. 62/082,007, filed Nov. 19, 2014. The contents and disclosures of which are incorporated herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
2350421 | Schoder et al. | Jun 1944 | A |
2470927 | Hale, Jr. | May 1949 | A |
3034403 | Neefe | May 1962 | A |
3270099 | Camp | Aug 1966 | A |
3458870 | Stone | Aug 1969 | A |
3578850 | Grant | May 1971 | A |
3776230 | Neefe | Dec 1973 | A |
3794414 | Wesley | Feb 1974 | A |
3877502 | Hunckler | Apr 1975 | A |
3996627 | Deeg et al. | Dec 1976 | A |
4010496 | Neefe | Mar 1977 | A |
4104338 | Guerrieri | Aug 1978 | A |
4116439 | Chavarria et al. | Sep 1978 | A |
4210391 | Cohen | Jul 1980 | A |
4298996 | Barnet | Nov 1981 | A |
4340283 | Cohen | Jul 1982 | A |
4402579 | Poler | Sep 1983 | A |
4423728 | Lieberman | Jan 1984 | A |
4435050 | Poler | Mar 1984 | A |
4450593 | Poler | May 1984 | A |
4505855 | Bruns et al. | Mar 1985 | A |
4563565 | Kampfer et al. | Jan 1986 | A |
4575373 | Johnson | Mar 1986 | A |
4607617 | Choyce | Aug 1986 | A |
4624669 | Grendahl | Nov 1986 | A |
4639105 | Neefe | Jan 1987 | A |
4646720 | Peyman et al. | Mar 1987 | A |
4655774 | Choyce | Apr 1987 | A |
4665913 | Esperance, Jr. | May 1987 | A |
4669466 | L'Esperance | Jun 1987 | A |
4669834 | Richter | Jun 1987 | A |
4676790 | Kern | Jun 1987 | A |
4676791 | LeMaster et al. | Jun 1987 | A |
4678422 | York | Jul 1987 | A |
4701038 | Neefe | Oct 1987 | A |
4715858 | Lindstrom | Dec 1987 | A |
4767647 | Bree | Aug 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4799784 | Safir | Jan 1989 | A |
4799931 | Lindstrom | Jan 1989 | A |
4807623 | Lindstrom | Feb 1989 | A |
4813955 | Achatz et al. | Mar 1989 | A |
4817789 | Paul | Apr 1989 | A |
4842599 | Bronstein | Jun 1989 | A |
4851003 | Lindstrom | Jul 1989 | A |
4863466 | Schlegel | Sep 1989 | A |
4881860 | Kanazawa | Nov 1989 | A |
4903695 | Warner et al. | Feb 1990 | A |
4907586 | Bille et al. | Mar 1990 | A |
4928815 | Paul | May 1990 | A |
4955904 | Atebara et al. | Sep 1990 | A |
4976732 | Vorosmarthy | Dec 1990 | A |
4994080 | Shepard | Feb 1991 | A |
5013319 | Davis | May 1991 | A |
5030230 | White | Jul 1991 | A |
5041133 | Sayano et al. | Aug 1991 | A |
5055602 | Melpolder | Oct 1991 | A |
5087015 | Galley | Feb 1992 | A |
5090955 | Simon | Feb 1992 | A |
5094521 | Jolson et al. | Mar 1992 | A |
5098443 | Parel et al. | Mar 1992 | A |
5112328 | Taboada et al. | May 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5120121 | Rawlings et al. | Jun 1992 | A |
5137441 | Fogarty | Aug 1992 | A |
5147395 | Willis | Sep 1992 | A |
5171318 | Gibson et al. | Dec 1992 | A |
5185107 | Blake | Feb 1993 | A |
5188494 | Hatin | Feb 1993 | A |
5192316 | Ting | Mar 1993 | A |
5196026 | Barrett et al. | Mar 1993 | A |
5213749 | Huss et al. | May 1993 | A |
5260727 | Oksman et al. | Nov 1993 | A |
5266241 | Parekh | Nov 1993 | A |
5269795 | Arnott | Dec 1993 | A |
5269812 | White | Dec 1993 | A |
5274404 | Michael | Dec 1993 | A |
5288436 | Liu et al. | Feb 1994 | A |
5292514 | Capecchi et al. | Mar 1994 | A |
5300116 | Chirila et al. | Apr 1994 | A |
5312330 | Klopotek | May 1994 | A |
5314439 | Sugita | May 1994 | A |
5314961 | Anton et al. | May 1994 | A |
5332802 | Kelman et al. | Jul 1994 | A |
5336261 | Barrett et al. | Aug 1994 | A |
5354331 | Schachar et al. | Oct 1994 | A |
5358520 | Patel | Oct 1994 | A |
5372580 | Simon et al. | Dec 1994 | A |
5391201 | Barrett et al. | Feb 1995 | A |
5441511 | Hanna | Aug 1995 | A |
5474548 | Knopp et al. | Dec 1995 | A |
5507740 | O'Donnell, Jr. | Apr 1996 | A |
5547468 | Simon et al. | Apr 1996 | A |
D375245 | Irving | Nov 1996 | S |
5578080 | McDonald | Nov 1996 | A |
5603774 | LeBoeuf et al. | Feb 1997 | A |
5607437 | Simon et al. | Mar 1997 | A |
5624456 | Hellenkamp | Apr 1997 | A |
5627613 | Kaneko | May 1997 | A |
5628794 | Lindstrom | May 1997 | A |
5628795 | Langerman | May 1997 | A |
5647865 | Swinger | Jul 1997 | A |
5653752 | Silvestrini et al. | Aug 1997 | A |
5662706 | Legerton et al. | Sep 1997 | A |
5693268 | Widman et al. | Dec 1997 | A |
5697923 | Poler | Dec 1997 | A |
5702440 | Portney | Dec 1997 | A |
5708049 | Katagiri et al. | Jan 1998 | A |
5713957 | Steele et al. | Feb 1998 | A |
5722971 | Peyman | Mar 1998 | A |
5725575 | O'Donnell, Jr. | Mar 1998 | A |
5746558 | Nygren et al. | May 1998 | A |
5752967 | Kritzinger et al. | May 1998 | A |
5769889 | Kelman | Jun 1998 | A |
5774202 | Abraham et al. | Jun 1998 | A |
5824086 | Silvestrini | Oct 1998 | A |
5837156 | Cumming | Nov 1998 | A |
5843105 | Mathis et al. | Dec 1998 | A |
5864128 | Plesko | Jan 1999 | A |
5870167 | Knopp et al. | Feb 1999 | A |
5895610 | Chang et al. | Apr 1999 | A |
5905561 | Lee et al. | May 1999 | A |
5910537 | Feingold et al. | Jun 1999 | A |
5913898 | Feingold et al. | Jun 1999 | A |
5919185 | Peyman | Jul 1999 | A |
5925294 | Shibuya | Jul 1999 | A |
5964748 | Peyman | Oct 1999 | A |
5964776 | Peyman | Oct 1999 | A |
5965330 | Evans et al. | Oct 1999 | A |
5980040 | Xu et al. | Nov 1999 | A |
6017121 | Chateau et al. | Jan 2000 | A |
6063073 | Peyman | May 2000 | A |
6090141 | Lindstrom | Jul 2000 | A |
6102946 | Nigam | Aug 2000 | A |
6106553 | Feingold et al. | Aug 2000 | A |
6110166 | Juhasz et al. | Aug 2000 | A |
6138307 | McDonald | Oct 2000 | A |
6152959 | Portney | Nov 2000 | A |
6164777 | Li et al. | Dec 2000 | A |
6178593 | Carlson | Jan 2001 | B1 |
6197019 | Peyman | Mar 2001 | B1 |
6201036 | Fedorov et al. | Mar 2001 | B1 |
6203538 | Peyman | Mar 2001 | B1 |
6210401 | Lai | Apr 2001 | B1 |
6217571 | Peyman | Apr 2001 | B1 |
6217596 | Farah | Apr 2001 | B1 |
6221067 | Peyman | Apr 2001 | B1 |
6228113 | Kaufman | May 2001 | B1 |
6228114 | Lee | May 2001 | B1 |
6228115 | Hoffmann et al. | May 2001 | B1 |
6171336 | Sawusch | Jun 2001 | B1 |
6264648 | Peyman | Jul 2001 | B1 |
6277146 | Peyman et al. | Aug 2001 | B1 |
6280470 | Peyman | Aug 2001 | B1 |
6280471 | Peyman et al. | Aug 2001 | B1 |
6302877 | Ruiz | Oct 2001 | B1 |
6304390 | Takanashi | Oct 2001 | B1 |
6308590 | Berto | Oct 2001 | B1 |
6335190 | Zhou et al. | Jan 2002 | B1 |
6361560 | Nigam | Mar 2002 | B1 |
6376153 | Uchikawa et al. | Apr 2002 | B2 |
6387379 | Goldberg et al. | May 2002 | B1 |
6391230 | Sarbadhikari | May 2002 | B1 |
6416179 | Lieberman et al. | Jul 2002 | B1 |
6423093 | Hicks et al. | Jul 2002 | B1 |
6432246 | Blake | Aug 2002 | B1 |
6436092 | Peyman | Aug 2002 | B1 |
6458141 | Peyman | Oct 2002 | B1 |
6461384 | Hoffmann et al. | Oct 2002 | B1 |
6491637 | Foster et al. | Dec 2002 | B2 |
6497700 | LaHaye | Dec 2002 | B1 |
6515006 | Horn | Feb 2003 | B2 |
6551307 | Peyman | Apr 2003 | B2 |
6554424 | Miller et al. | Apr 2003 | B1 |
6554860 | Hoffmann et al. | Apr 2003 | B2 |
6555103 | Leukel et al. | Apr 2003 | B2 |
6575573 | Lai et al. | Jun 2003 | B2 |
6581993 | Nigam | Jun 2003 | B2 |
6588902 | Isogai | Jul 2003 | B2 |
6589280 | Koziol | Jul 2003 | B1 |
6607527 | Ruiz et al. | Aug 2003 | B1 |
6613088 | Babizhayev | Sep 2003 | B1 |
6638304 | Azar | Oct 2003 | B2 |
6648741 | Schneider | Nov 2003 | B2 |
6649722 | Rosenzweig et al. | Nov 2003 | B2 |
6655804 | Streibig | Dec 2003 | B2 |
6692126 | Xie et al. | Feb 2004 | B1 |
6702807 | Peyman | Mar 2004 | B2 |
6726322 | Andino et al. | Apr 2004 | B2 |
6740116 | Morcher | May 2004 | B2 |
6755858 | White | Jun 2004 | B1 |
6786926 | Peyman | Sep 2004 | B2 |
6811256 | Becherer et al. | Nov 2004 | B1 |
6855163 | Peyman | Feb 2005 | B2 |
6874886 | Miller et al. | Apr 2005 | B2 |
6899424 | Miller et al. | May 2005 | B2 |
6949093 | Peyman | Sep 2005 | B1 |
6951556 | Epstein | Oct 2005 | B2 |
6966648 | Miller et al. | Nov 2005 | B2 |
6989008 | Peyman | Jan 2006 | B2 |
7001374 | Peyman | Feb 2006 | B2 |
7008447 | Koziol | Mar 2006 | B2 |
7025455 | Roffman | Apr 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7099057 | Parker et al. | Aug 2006 | B2 |
7276080 | Murakami et al. | Oct 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7364674 | Hoover | Apr 2008 | B1 |
7399811 | Mentak et al. | Jul 2008 | B2 |
7404637 | Miller et al. | Jul 2008 | B2 |
7404638 | Miller et al. | Jul 2008 | B2 |
7446157 | Mentak et al. | Nov 2008 | B2 |
7455404 | Bandhauer et al. | Nov 2008 | B2 |
7455691 | Feingold et al. | Nov 2008 | B2 |
7477452 | Tsuruma | Jan 2009 | B2 |
7491350 | Silvestrini | Feb 2009 | B2 |
7497866 | Perez | Mar 2009 | B2 |
7628810 | Christie et al. | Dec 2009 | B2 |
7641337 | Altmann | Jan 2010 | B2 |
7645299 | Koziol | Jan 2010 | B2 |
7745555 | Mentak et al. | Jun 2010 | B2 |
7842367 | Mentak | Nov 2010 | B2 |
7976577 | Silvestrini | Jul 2011 | B2 |
D645337 | Hsu et al. | Sep 2011 | S |
8043371 | Paul et al. | Oct 2011 | B2 |
8048972 | Mentak et al. | Nov 2011 | B2 |
8079706 | Silvestrini et al. | Dec 2011 | B2 |
D656526 | Christie et al. | Mar 2012 | S |
8241354 | Hong et al. | Aug 2012 | B2 |
8287592 | Silvestrini | Oct 2012 | B2 |
8343215 | Miller et al. | Jan 2013 | B2 |
D681086 | Christie et al. | Apr 2013 | S |
8420753 | Mentak et al. | Apr 2013 | B2 |
8460374 | Christie et al. | Jun 2013 | B2 |
8604098 | Boydston et al. | Dec 2013 | B2 |
8740978 | Weeber et al. | Jun 2014 | B2 |
8752958 | Miller et al. | Jun 2014 | B2 |
8858624 | Christie et al. | Oct 2014 | B2 |
8864824 | Silvestrini et al. | Oct 2014 | B2 |
9005281 | Christie et al. | Apr 2015 | B2 |
9138142 | Christie et al. | Sep 2015 | B2 |
9204962 | Silvestrini | Dec 2015 | B2 |
9427311 | Christie et al. | Aug 2016 | B2 |
9427922 | Reboul et al. | Aug 2016 | B2 |
9492272 | Christie et al. | Nov 2016 | B2 |
9545303 | Vilupuru et al. | Jan 2017 | B2 |
9573328 | Reboul et al. | Feb 2017 | B2 |
9603704 | Silvestrini | Mar 2017 | B2 |
20120238091 | Hsieh et al. | May 1994 | A |
20010027314 | Peyman | Oct 2001 | A1 |
20010034516 | Peyman | Oct 2001 | A1 |
20010050750 | Breger | Dec 2001 | A1 |
20020010510 | Silverstrini | Jan 2002 | A1 |
20020082288 | Horn | Jun 2002 | A1 |
20020120329 | Lang et al. | Aug 2002 | A1 |
20020167640 | Francis et al. | Nov 2002 | A1 |
20020196409 | Jani | Dec 2002 | A1 |
20030014042 | Juhasz et al. | Jan 2003 | A1 |
20030105521 | Perez | Jun 2003 | A1 |
20030135272 | Brady et al. | Jul 2003 | A1 |
20030149480 | Shadduck | Aug 2003 | A1 |
20030204258 | Graham et al. | Oct 2003 | A1 |
20030216763 | Patel | Nov 2003 | A1 |
20040019379 | Glick et al. | Jan 2004 | A1 |
20040056371 | Liao et al. | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040106929 | Masket | Jun 2004 | A1 |
20050027355 | Murakami et al. | Feb 2005 | A1 |
20050046794 | Silvestrini et al. | Mar 2005 | A1 |
20050090895 | Peyman | Apr 2005 | A1 |
20050124983 | Frey et al. | Jun 2005 | A1 |
20050137703 | Chen | Jun 2005 | A1 |
20050143751 | Makker et al. | Jun 2005 | A1 |
20050182488 | Peyman | Aug 2005 | A1 |
20050187621 | Brady | Aug 2005 | A1 |
20050288784 | Peyman | Dec 2005 | A1 |
20060064077 | Peyman | Mar 2006 | A1 |
20060079959 | Christie et al. | Apr 2006 | A1 |
20060113054 | Silvestrini | Jun 2006 | A1 |
20060184243 | Yilmaz | Aug 2006 | A1 |
20060232665 | Schowengerdt et al. | Oct 2006 | A1 |
20060235428 | Silvestrini | Oct 2006 | A1 |
20060235514 | Silvestrini | Oct 2006 | A1 |
20060241751 | Marmo et al. | Oct 2006 | A1 |
20060265058 | Silvestrini | Nov 2006 | A1 |
20060268226 | Christie et al. | Nov 2006 | A1 |
20060268227 | Christie et al. | Nov 2006 | A1 |
20060268228 | Christie et al. | Nov 2006 | A1 |
20060268229 | Silvestrini et al. | Nov 2006 | A1 |
20060270946 | Silvestrini et al. | Nov 2006 | A1 |
20060271026 | Silvestrini et al. | Nov 2006 | A1 |
20060271178 | Christie et al. | Nov 2006 | A1 |
20060271179 | Christie et al. | Nov 2006 | A1 |
20060271180 | Christie et al. | Nov 2006 | A1 |
20060271181 | Christie et al. | Nov 2006 | A1 |
20060271182 | Christie et al. | Nov 2006 | A1 |
20060271183 | Christie et al. | Nov 2006 | A1 |
20060271184 | Silvestrini | Nov 2006 | A1 |
20060271185 | Silvestrini | Nov 2006 | A1 |
20060274264 | Christie et al. | Dec 2006 | A1 |
20060274265 | Christie et al. | Dec 2006 | A1 |
20070032866 | Portney | Feb 2007 | A1 |
20070092592 | Chiang | Apr 2007 | A1 |
20070129797 | Lang et al. | Jun 2007 | A1 |
20070225691 | Silvestrini et al. | Sep 2007 | A1 |
20080033546 | Liang | Feb 2008 | A1 |
20080077238 | Deacon et al. | Mar 2008 | A1 |
20080100921 | Nishikawa | May 2008 | A1 |
20080151183 | Altmann | Jun 2008 | A1 |
20080208335 | Blum et al. | Aug 2008 | A1 |
20080212030 | Bentley et al. | Sep 2008 | A1 |
20080220214 | Uozu | Sep 2008 | A1 |
20080221674 | Blum et al. | Sep 2008 | A1 |
20080255663 | Akpek et al. | Oct 2008 | A1 |
20080269884 | Vannoy | Oct 2008 | A1 |
20080306587 | Your | Dec 2008 | A1 |
20090012505 | Chernyak | Jan 2009 | A1 |
20090021692 | Miller et al. | Jan 2009 | A1 |
20090287306 | Smith et al. | Jan 2009 | A1 |
20090059168 | Miller et al. | Mar 2009 | A1 |
20090069817 | Peyman | Mar 2009 | A1 |
20090171458 | Kellan et al. | Jul 2009 | A1 |
20090204207 | Blum et al. | Aug 2009 | A1 |
20090222086 | Lui et al. | Sep 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090306773 | Silvestrini et al. | Dec 2009 | A1 |
20100082100 | Mikawa | Apr 2010 | A1 |
20100127412 | Lake | May 2010 | A1 |
20100149618 | Sprague | Jun 2010 | A1 |
20100312336 | Hong et al. | Dec 2010 | A1 |
20110037184 | Shoji et al. | Feb 2011 | A1 |
20110040376 | Christie et al. | Feb 2011 | A1 |
20110125261 | Portney | May 2011 | A1 |
20110166652 | Bogaert et al. | Jul 2011 | A1 |
20110172675 | Danta et al. | Jul 2011 | A1 |
20110251685 | Chu | Oct 2011 | A1 |
20120109294 | Olson | May 2012 | A1 |
20120143325 | Christie et al. | Jun 2012 | A1 |
20120203239 | Vukich et al. | Aug 2012 | A1 |
20120245683 | Christie et al. | Sep 2012 | A1 |
20120310338 | Christie et al. | Dec 2012 | A1 |
20130053953 | Silvestrini | Feb 2013 | A1 |
20130131795 | Miller et al. | May 2013 | A1 |
20130268071 | Vilupuru et al. | Oct 2013 | A1 |
20140131905 | Webb | May 2014 | A1 |
20140264981 | Reboul et al. | Sep 2014 | A1 |
20140277432 | Silvestrini | Sep 2014 | A1 |
20140379078 | Trindade | Dec 2014 | A1 |
20150025627 | Christie et al. | Jan 2015 | A1 |
20150073549 | Webb et al. | Mar 2015 | A1 |
20150183173 | Linhardt et al. | Jul 2015 | A1 |
20150366658 | Christie et al. | Dec 2015 | A1 |
20160081794 | Silvestrini | Mar 2016 | A1 |
20160229134 | Reboul et al. | Aug 2016 | A1 |
20170143477 | Christie et al. | May 2017 | A1 |
20170144392 | Reboul et al. | May 2017 | A1 |
20170189167 | Vilupuru et al. | Jul 2017 | A1 |
Number | Date | Country |
---|---|---|
2004201751 | May 2004 | AU |
1875895 | Dec 2006 | CN |
101322663 | Dec 2008 | CN |
4134320 | Apr 1992 | DE |
0165652 | Dec 1985 | EP |
0443094 | Aug 1991 | EP |
1173790 | Jan 2002 | EP |
1674049 | Jun 2006 | EP |
1548489 | Aug 2006 | EP |
2319457 | May 2011 | EP |
2243052 | Sep 2011 | EP |
2365379 | Sep 2011 | EP |
2455799 | May 2012 | EP |
2823789 | Jan 2015 | EP |
2364457 | Aug 2015 | EP |
2620687 | Mar 1989 | FR |
2649605 | Jan 1991 | FR |
1276003 | Jun 1972 | GB |
62-167343 | Jul 1987 | JP |
64-002644 | Jan 1989 | JP |
H02-7954 | Jan 1990 | JP |
04-158859 | Jun 1992 | JP |
06-509731 | Mar 1993 | JP |
H05-65340 | Sep 1993 | JP |
06-502782 | Mar 1994 | JP |
H07-067896 | Mar 1995 | JP |
07-265340 | Oct 1995 | JP |
08-103457 | Apr 1996 | JP |
H09-502542 | Mar 1997 | JP |
11-503657 | Aug 1997 | JP |
07-178125 | Jul 1998 | JP |
2000-047145 | Feb 2000 | JP |
2002-537895 | Nov 2002 | JP |
2003-502109 | Jan 2003 | JP |
2004-510199 | Apr 2004 | JP |
2004-538034 | Dec 2004 | JP |
2005-533576 | Nov 2005 | JP |
2007-516794 | Jun 2007 | JP |
2007-523720 | Aug 2007 | JP |
2008-506710 | Mar 2008 | JP |
S59-54527 | May 2008 | JP |
10-0335722 | May 2002 | KR |
2138837 | Sep 1999 | RU |
1380743 | Mar 1988 | SU |
WO 8705797 | Oct 1987 | WO |
WO 9503747 | Feb 1995 | WO |
WO 9508135 | Mar 1995 | WO |
WO 9635397 | Nov 1996 | WO |
WO 9848715 | Nov 1998 | WO |
WO 00025704 | May 2000 | WO |
WO 00038594 | Jul 2000 | WO |
WO 0051682 | Sep 2000 | WO |
WO 0052516 | Sep 2000 | WO |
WO 0070388 | Nov 2000 | WO |
WO 2001010641 | Feb 2001 | WO |
WO 0115779 | Mar 2001 | WO |
WO 0117460 | Mar 2001 | WO |
WO 0119364 | Mar 2001 | WO |
WO 01082815 | Nov 2001 | WO |
WO 02076320 | Oct 2002 | WO |
WO 02102241 | Dec 2002 | WO |
WO 03020177 | Mar 2003 | WO |
WO 03022168 | Mar 2003 | WO |
WO 03061518 | Jul 2003 | WO |
WO 2004014969 | Feb 2004 | WO |
WO 2004034917 | Apr 2004 | WO |
WO 2004105588 | Dec 2004 | WO |
WO 2004113959 | Dec 2004 | WO |
WO 2005082265 | Sep 2005 | WO |
WO 2005020638 | Feb 2006 | WO |
WO 2006047534 | May 2006 | WO |
WO 2006060380 | Jun 2006 | WO |
WO 2006113377 | Oct 2006 | WO |
WO 2006113411 | Oct 2006 | WO |
WO 2006113563 | Oct 2006 | WO |
WO 2006113564 | Oct 2006 | WO |
WO 2007057734 | Oct 2007 | WO |
WO 2007133384 | Nov 2007 | WO |
WO 2007142981 | Dec 2007 | WO |
WO 2008036671 | Mar 2008 | WO |
WO 2008102096 | Aug 2008 | WO |
WO 2009050511 | Apr 2009 | WO |
WO 2009122409 | Oct 2009 | WO |
WO 2009140080 | Nov 2009 | WO |
WO 2009149060 | Dec 2009 | WO |
WO 2010059214 | May 2010 | WO |
WO 2011020074 | Feb 2011 | WO |
WO 2011020078 | Feb 2011 | WO |
WO 2011047076 | Apr 2011 | WO |
WO 2011069059 | Jun 2011 | WO |
WO 2011088107 | Jul 2011 | WO |
WO 2012170066 | Dec 2012 | WO |
WO 2013019871 | Feb 2013 | WO |
WO 2013082545 | Jun 2013 | WO |
WO 2013101793 | Jul 2013 | WO |
WO 2013112589 | Aug 2013 | WO |
WO 2013123265 | Aug 2013 | WO |
WO 2014054946 | Apr 2014 | WO |
WO 2014074610 | May 2014 | WO |
WO 2014158653 | Oct 2014 | WO |
WO 2015021323 | Feb 2015 | WO |
WO 2015069927 | May 2015 | WO |
WO 2015073718 | May 2015 | WO |
WO 2016081493 | May 2016 | WO |
WO 2017062316 | Apr 2017 | WO |
WO 2017091520 | Jun 2017 | WO |
Entry |
---|
Internet Archive Wayback Machine; Aniridia Implants; downloaded from https://web.archive.org/web/20110824062840/http://www.morcher.com/nc/produkte/aniridiaimplants.html (Archived Aug. 24, 2011; printed on Feb. 5, 2015). |
Guyton A.C., Textbook of Medical Physiology, 7th Edition, W.B. Saunders Company, Jan. 1986: Chapter 58, pp. 700-710. |
Lu Xuequan, et al. “Radiation preparation and thermo-response swelling of interpenetrating polymer network hydrogel composed of PNIPAAm and PMMA”, Radiation Physics and Chemistry, vol. 57, Mar. 2000, pp. 477-480, XP002473596. |
Patel, C.K., et al. “Imaging the macula through a black occlusive intraocular lens”. Arch. Ophthalmol. Oct. 2010; 128(10):1374-1376. |
Yusuf, et al., “Inability to perform posterior segment monitoring by scanning laser ophthalmoscopy or optical coherence tomography with some occlusive intraocular lenses in clinical use”, J. Cataract Refract. Surg., Mar. 2012, 38: 513-513. |
Yusuf, et al., “Occlusive IOLs for Intractable Diplopia Demonstrate a Novel Near-Infrared Window of Transmission for SLO/OCT Imaging and Clinical Assessment”. Investigative Ophthalmology & Visual Science, May 2011, 52(6): 3737-3743. |
International Search Report and Written Opinion for PCT/US2015/061143 dated Feb. 29, 2016 in 11 pages. |
Number | Date | Country | |
---|---|---|---|
20160135947 A1 | May 2016 | US |
Number | Date | Country | |
---|---|---|---|
62082007 | Nov 2014 | US |